Metabolife defense verdict
This article was originally published in The Tan Sheet
Executive Summary
Supplement marketer's conduct did not cause an Upland, Calif. man's personal injuries, Rancho Cucamonga, Calif. state court jury concludes Dec. 12. Plaintiff Tom Hendriksen alleged he suffered a stroke at age 47 after using ephedra-containing Metabolife 356. Company argued plaintiff had numerous risk factors contraindicated on product labeling - including diabetes, hypertension, high cholesterol, atherosclerosis - and there was no proof the product caused his injury. Even though jury found Metabolife liable for design defect, negligence, false representation and concealment of a material fact, panel did not award any damages and concluded company did not breach an express warranty of safety. This is the second personal injury lawsuit to go to verdict against Metabolife and the first to result in a no damages award; an Alabama jury returned a $4.1 mil. verdict in four consolidated cases last month (1"The Tan Sheet" Nov. 25, 2002, p. 3)...
You may also be interested in...
Metabolife 356 “Unreasonably Dangerous,” Jury Says In $4.1 Mil. Verdict
Metabolife sold its ephedrine alkaloid-containing Metabolife 356 in a "defective condition unreasonably dangerous to an ultimate user," a Birmingham, Ala. federal jury concluded in four cases Nov. 19
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.